CNTA
Centessa Pharmaceuticals plc · Healthcare
Insiders sold $2.0M net in the last 90 days ·4 sellers, 0 buyers· 2 of 4 sales under Rule 10b5-1 plans· latest Form 4 filed Jun 24, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13.3M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Jun 24, 2026
Medicxi Ventures Management (Jersey) Ltd
Centessa Pharmaceuticals plc (CNTA) has 34 SEC Form 4 filings (71 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jun 24, 2026.
Inside the rolling window, 7 insiders at Centessa Pharmaceuticals plc reported no open-market purchases and 16 open-market sales totaling $13.3M. The most active filer is Chief People Officer Anderson Karen M. with 4 filings. Insiders have net sold $10.1M over the trailing 6 months. The most recent open-market filing is a sale of 19,963,157 shares by 10% Owner Medicxi Ventures Management (Jersey) Ltd, dated Jun 24, 2026.
- Industry:Biotechnology
- CEO:Mario Alberto Accardi
- Employees:129
- HQ:Altrincham, GB
- IPO:2021-05-28
| Source | |||||||
|---|---|---|---|---|---|---|---|
Medicxi Ventures Management (Jersey) LtdFirst filing | 10% Owner | Sale | 19,963,157 | — | Jun 24 | +0.0% | SEC ↗ |
INDEX VENTURES LIFE VI (JERSEY) L.P.First filing | 10% Owner | Sale | 9,961,789 | — | Jun 24 | +0.0% | SEC ↗ |
| Chief People Officer | Sale | 41,076 | $1.2M | Mar 27 | +41.1% | SEC ↗ | |
| Chief Business Officer | Sale | 23,998 | $720K | Mar 26 | +37.8% | SEC ↗ | |
| Chief People Officer | Sale | 64,768 | $1.8M | Mar 18 | — | SEC ↗ | |
| Chief People Officer | Sale | 10,043 | $282K | Mar 18 | — | SEC ↗ | |
| Chief People Officer | Sale | 120,029 | $3.2M | Mar 16 | — | SEC ↗ | |
Weinhoff Gregory MFirst filing | Chief Business Officer | Sale | 73,196 | $1.9M | Mar 13 | — | SEC ↗ |
| Chief Legal Officer | Sale | 1,010 | $25K | Feb 3 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 38,951 | $980K | Feb 3 | — | SEC ↗ | |
| President, Orexin Program | Sale | 10,000 | $288K | Dec 9 | — | SEC ↗ | |
| President, Orexin Program | Sale | 10,000 | $300K | Dec 8 | — | SEC ↗ | |
HUSSAIN IQBAL JFirst filing | General Counsel | Sale | 6,000 | $166K | Nov 18 | — | SEC ↗ |
| Chief Technology & Quality Ofc | Sale | 40,000 | $1.1M | Nov 18 | — | SEC ↗ | |
Bush Tia LFirst filing | Chief Technology & Quality Ofc | Sale | 40,000 | $1.0M | Nov 13 | — | SEC ↗ |
Accardi Mario AlbertoFirst filing | President, Orexin Program | Sale | 8,000 | $200K | Oct 27 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does CNTA have?
Centessa Pharmaceuticals plc (CNTA) has 34 SEC Form 4 filings (71 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Jun 24, 2026.
When was the most recent SEC Form 4 filing for CNTA?
The most recent Form 4 filing for CNTA on Tracefour is dated Jun 24, 2026.
Who is the most active insider at CNTA?
The most active SEC Form 4 filer at CNTA in the rolling window is Chief People Officer Anderson Karen M., with 4 filings.
What is the net insider flow at CNTA over the last 6 months?
Over the trailing 180 days, insiders at CNTA have net sold $10.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CNTA in the current window?
Inside the rolling window, insiders at CNTA bought $0 and sold $13.3M based on SEC Form 4 filings.
Can I get alerts for CNTA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Centessa Pharmaceuticals plc (CNTA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Centessa Pharmaceuticals plc is in the Healthcare sector.